N@N

Sumant Kulkarni Maintained (ACAD) at Strong Buy with Decreased Target to $38 on, Aug 3rd, 2023

Sumant Kulkarni of Canaccord Genuity, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Strong Buy with Decreased Target from $39 to $38 on, Aug 3rd, 2023.

Sumant has made no other calls on ACAD in the last 4 months.

There are 6 other peers that have a rating on ACAD. Out of the 6 peers that are also analyzing ACAD, 3 agree with Sumant's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Neena Bitritto-Garg of "Citigroup" Maintained at Hold with Increased Target to $27 on, Friday, July 14th, 2023
• Uy Ear of "Mizuho" Reiterated at Hold and Held Target at $20 on, Wednesday, June 14th, 2023
• Tazeen Ahmad of "B of A Securities" Maintained at Hold with Increased Target to $26 on, Monday, May 22nd, 2023

These are the ratings of the 3 analyists that currently disagree with Sumant

---

• Sarah James of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $42 on, Monday, July 17th, 2023
• Gregory Renza of "RBC Capital" Maintained at Buy with Increased Target to $33 on, Friday, July 14th, 2023
• Jason Butler of "JMP Securities" Maintained at Buy with Increased Target to $39 on, Friday, July 14th, 2023

Contributing Sources

---